Skip to main content

Table 4 Univariate and multivariate analysis of CRC-specific mortality with in 1,3 and 5 years since diagnosis during (2009–2017) a

From: Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study

Characteristics

Total

Univariate

Multivariate

 

N

baHR

95% CI

aHR

95% CI

Diagnosis period

 2009–2011

288

 

 2012–2014

395

0.99

(0.74,1.31)

0.91

(0.67, 1.24)

 2015–2017

329

0.96

(0.69,1.34)

0.76

(0.52, 1.12)

Age

  < =40

40

1.87

(1.09,3.47)

1.72

(0.49, 6.07)

 41–50

68

1.03

(0.58,1.54)

0.73

(0.25, 2.13)

 51–60

186

1.02

(0.67,1.54)

0.79

(0.39, 1.59)

 61–70

288

 71–80

237

1.53

(1.09.3.5)

1.29

(0.72, 2.35)

  > =81

193

2.51

(1.8, 3.5)

1.36

(0.65, 2.84)

Gender

 Female

430

1.2

(0.92,1.48)

1.002

(0.77, 1.31)

 Male

582

  

Marital status

 Single

55

0.91

(0.51,1.63)

0.86

(0.45, 1.61)

 Married

748

 Widowed/divorced

57

1.41

(0.86,2.31)

1.04

(0.6, 1.81)

 Unknown

142

0.91

(.068,1.43)

0.92

(0.62, 1.36)

Nationality

 Non-Saudi

76

0.66

(0.37,1.18)

0.65

(0.35, 1.19)

 Saudi

936

Tumor Site

 Right colon

184

 Left colon

434

0.77

(0.54,1.11)

0.72

(0.49, 1.04)

 Colon-non specified

160

1.12

(0.76, 1.62)

0.88

(0.58, 1.34)

 Rectum

234

1.01

(0.68, 1.51)

0.98

(0.63, 1.54)

Tumor grade

 Well differentiated

33

 Moderately differentiated

774

0.73

(0.38, 1.37)

0.76

(0.38, 1.49)

 (Poorly differentiated/Anaplastic))

67

1.98

(0.95, 4.11)

1.52

(0.69, 3.31)

 Unknown

138

1.7

(0.86, 3.33)

1.08

(0.51, 2.75)

Stage at diagnosis

 Localized

186

 Regional

362

1.89

(1.17,3.04)

2.51

(2.51, 4.13)

 Distant metastasis

225

9.01

(5.79,14.71)

11.43

(7.04, 18.55)

 Unknown

76

5.51

(2.71,11.49)

4.87

(2.28, 10.37)

Basis of diagnosis

 Histology of primary

972

 Histology of metastases

28

4.89

(2.98, 8.04)

1.67

(0.92, 3.04)

 Others

12

6.42

(3.45,11.78)

7.17

(0.92, 3.04)

Morphology

 Adenocarcinoma (AC), NOS

854

 Mucinous AC

63

1.07

(0.64,1.78)

0.78

(0.45, 1.36)

 Mucin-producing AC

12

1.62

(0.66,3.93)

1.58

(0.63, 3.94)

 Signet ring cell carcinoma

14

5.07

(2.59,9.91)

1.65

(0.75, 3.61)

 AC in villous/tubuvillous adenoma

16

0.071

(0.22,2.21)

0.96

(0.30, 3.08)

 Others

53

1.68

(1.08,2.61)

0.62

(0.33, 1.21)

Surgery

 Yes

426

 No

586

2.48

(1.92,3.19)

1.36

(1.007,1.83)

Chemotherapy

 Yes

411

 No

601

1.39

(1.07,1.74)

1.65

(1.17, 2.33)

Radiotherapy

 Yes

95

 No

917

1.26

(0.82, 1.93)

0.79

(0.49, 1.31)

  1. a Data represent Saudi patients registered in the MNG-HA hospitals system between January 1, 2009, and December 31, 2017
  2. b aHR: Adjusted hazard ratio. Adjusted for all variables in Table 2
  3. Bolded aHR indicates significant p-value